Maravai LifeSciences Holdings, Inc.
Simbolis: MRVI
NASDAQ
8.87
USDRinkos kaina šiandien
-9.7422
P/E santykis
-0.1333
PEG koeficientas
1.18B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Maravai LifeSciences Holdings, Inc. (MRVI) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2296.43 | 575 | 632.1 | 551.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 200.74 | 55.7 | 146.8 | 117.5 | ||||||
balance-sheet.row.inventory | 197.79 | 51.4 | 43.2 | 51.6 | ||||||
balance-sheet.row.other-current-assets | 73.01 | 17.8 | 25.8 | 19.7 | ||||||
balance-sheet.row.total-current-assets | 2767.97 | 699.9 | 847.9 | 740 | ||||||
balance-sheet.row.property-plant-equipment-net | 807.33 | 222.6 | 116.6 | 46.3 | ||||||
balance-sheet.row.goodwill | 1304.55 | 326 | 283.7 | 152.8 | ||||||
balance-sheet.row.intangible-assets | 897.69 | 221 | 216.7 | 117.6 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 2202.23 | 547 | 500.3 | 270.3 | ||||||
balance-sheet.row.long-term-investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.tax-assets | 1764.23 | 0 | 765.8 | 808.1 | ||||||
balance-sheet.row.other-non-current-assets | -113.5 | 9.3 | 40.3 | 52.9 | ||||||
balance-sheet.row.total-non-current-assets | 4696.11 | 787.5 | 1434.4 | 1178.2 | ||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-assets | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.account-payables | 35.04 | 10.7 | 6 | 8.2 | ||||||
balance-sheet.row.short-term-debt | 45.01 | 12.9 | 11.7 | 9.7 | ||||||
balance-sheet.row.tax-payables | 1 | 1 | 1 | 1.4 | ||||||
balance-sheet.row.long-term-debt-total | 2192.18 | 518.7 | 573.6 | 524.6 | ||||||
Deferred Revenue Non Current | 829.37 | 79.4 | 0 | 0 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 21.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 209.03 | 60.5 | 89.4 | 65.7 | ||||||
balance-sheet.row.total-non-current-liabilities | 3807.23 | 610.1 | 1266.9 | 1279.1 | ||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.capital-lease-obligations | 285.32 | 79.4 | 57.8 | 3.7 | ||||||
balance-sheet.row.total-liab | 4106.89 | 697.6 | 1377.1 | 1372.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 10.05 | 2.5 | 2.6 | 2.6 | ||||||
balance-sheet.row.retained-earnings | 1349.25 | 285.7 | 404.8 | 184.6 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.other-total-stockholders-equity | 507.98 | 128.5 | 137.9 | 128.4 | ||||||
balance-sheet.row.total-stockholders-equity | 1867.28 | 416.8 | 545.2 | 315.5 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.minority-interest | 1489.91 | 373.1 | 360 | 229.9 | ||||||
balance-sheet.row.total-equity | 3357.19 | 789.9 | 905.2 | 545.4 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 7464.08 | - | - | - | ||||||
Total Investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.total-debt | 2398.63 | 611 | 585.3 | 534.3 | ||||||
balance-sheet.row.net-debt | 102.2 | 36 | -46.9 | -17 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -147.04 | -119 | 490.7 | 469.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.53 | 48.8 | 38.1 | 24.8 | ||||||
cash-flows.row.deferred-income-tax | 756.46 | 754.9 | 42.3 | 46.9 | ||||||
cash-flows.row.stock-based-compensation | 40.66 | 34.6 | 18.7 | 10.5 | ||||||
cash-flows.row.change-in-working-capital | 29.5 | 97.8 | -45.1 | -176.6 | ||||||
cash-flows.row.account-receivables | 19.87 | 84.4 | -22.3 | -70.4 | ||||||
cash-flows.row.inventory | 4.85 | 0.6 | 9.5 | -21.6 | ||||||
cash-flows.row.account-payables | 1.84 | 5.3 | -1.6 | 0.7 | ||||||
cash-flows.row.other-working-capital | 17.96 | 7.5 | -30.7 | -85.3 | ||||||
cash-flows.row.other-non-cash-items | -686.93 | -690.9 | -8.7 | -6.2 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 32.68 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.acquisitions-net | 75.02 | -69.6 | -238.3 | 120 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | 6.42 | 12.9 | -12.2 | 0.5 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -56.82 | -122.3 | -267.6 | 105.7 | ||||||
cash-flows.row.debt-repayment | -5.92 | -5.8 | -13.9 | -6 | ||||||
cash-flows.row.common-stock-issued | -1.45 | 0 | 2.4 | 1.7 | ||||||
cash-flows.row.common-stock-repurchased | -0.35 | 0 | 0 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-financing-activites | -35.07 | -55.3 | -176 | -154.8 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -42.44 | -61.1 | -187.5 | -159 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 1.6 | 0 | -0.1 | ||||||
cash-flows.row.net-change-in-cash | -66.58 | -57.2 | 80.9 | 315.1 | ||||||
cash-flows.row.cash-at-end-of-period | 2296.43 | 575 | 632.1 | 551.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 2363.02 | 632.1 | 551.3 | 236.2 | ||||||
cash-flows.row.operating-cash-flow | 32.68 | 126.2 | 536 | 368.6 | ||||||
cash-flows.row.capital-expenditure | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.free-cash-flow | -30.67 | 60.7 | 518.9 | 353.7 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 274.1 | 288.9 | 883 | 799.2 | ||||||
income-statement-row.row.cost-of-revenue | 154 | 151.3 | 169 | 140.6 | ||||||
income-statement-row.row.gross-profit | 120.1 | 137.6 | 714 | 658.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 18.17 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.other-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.operating-expenses | 166.92 | 141.8 | 147.6 | 115.3 | ||||||
income-statement-row.row.cost-and-expenses | 320.92 | 293.1 | 316.6 | 255.8 | ||||||
income-statement-row.row.interest-income | 28.89 | 27.7 | 2.3 | 30.3 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.total-operating-expenses | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.depreciation-and-amortization | 25.72 | 48.8 | -5.8 | -11 | ||||||
income-statement-row.row.ebitda-caps | -19.96 | - | - | - | ||||||
income-statement-row.row.operating-income | -45.68 | -4.2 | 574.2 | 554.6 | ||||||
income-statement-row.row.income-before-tax | 599.85 | 617.7 | 551.5 | 530.8 | ||||||
income-statement-row.row.income-tax-expense | 759.56 | 756.1 | 60.8 | 61.5 | ||||||
income-statement-row.row.net-income | -131.04 | -119 | 490.7 | 469.3 |
Dažnai užduodami klausimai
Kas yra Maravai LifeSciences Holdings, Inc. (MRVI) bendras turtas?
Maravai LifeSciences Holdings, Inc. (MRVI) bendras turtas yra 1487450000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 138320000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.483.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.459.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.416.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.100.
Kas yra Maravai LifeSciences Holdings, Inc. (MRVI) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -119029000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 610967000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 141799000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 561691000.000.